Also of note is that, sacubitril/valsartan was observed to inhibit myocardial fibrosis more significantly than its effects on myocardial TGF-β1 and p-Smads protein expression, which suggests that other mechanisms besides inhibition of the TGF-β1/Smads signaling pathway are involved in the cardioprotective effects of sacubitril/valsartan after myocardial infarction. The gene discussed is TGFB1; the disease is myocardial infarction.